替雷利珠单抗相关药物不良反应文献分析

目的：归纳替雷利珠单抗引起药物不良反应（adverse drug reactions，ADRs）的特点，为临床用药安全提供参考。方法：检索中国知网、万方、维普、PubMed、ScienceDirect 和 Embase 数据库（截至2022年4月），收集关于替雷利珠单抗相关ADRs的个案报道，对纳入病例的临床资料、替雷利珠单抗用药情况以及ADRs的临床表现、名称、发生时间、处置及转归等进行统计分析。结果：纳入替雷利珠单抗致ADRs的个案报道15篇，共计16例患者，其中男性11例，女性5例；年龄26~78岁，平均年龄（64.81±12.92）岁。ADRs发生时间在1个用药周期内的有4例，2个用药周期内的有2例，3~9周期时间内8例，10个周期后的有2例；涉及皮肤软组织、内分泌、消化、泌尿和心血管等系统，经对症治疗后，16例患者均好转。结论：临床使用中应加强替雷利珠单抗相关ADRs的关注，提高临床用药安全性。

Literature analysis of adverse drug reactions induced by tislelizumab

OBJECTIVE To summarize the characteristics of adverse drug reactions (ADRs) induced by tislelizumab, and provide reference for clinical medication safety.METHODS ADRs induced by tislelizumab reported in domestic and foreign databases of CNKI, Wanfang, VIP, PubMed, ScienceDirect and Embase databases (up to April 2022) were collected. Statistical analysis was conducted on the clinical data of patients and their ADRs.RESULTS Totally 15 papers of ADRs induced by tislelizumab were included, involving16 patients(11 males and 5 females). The patients' ages ranged from 26 to 78 years, with an average age of (64.81±12.92) years. ADRs occurred within one medication cycle in 4 patients, 2 medication cycles in 2 patients, 3-9 cycles in 8 patients, and 10 cycles in 2 patients. ADRs involved skin and soft tissue system, endocrine system, digestive system, urinary system and cardiovascular system, etc. After symptomatic treatment, all of the 16 patients were improved.CONCLUSION More attention should be paid to ADRs induced by tislelizumab in clinical practice.